Histogen targets skin care market with new cosmeceutical venture
Histogen, which calls itself a regenerative medicine company, is launching a new venture Histogen Aesthetics to develop products for the medical aesthetics industry.
Skin, hair and nail products
Products from the venture will be launched early 2009 and will include skin, hair and nail care products all based on the company’s ReGenica complex.
The complex includes growth factors, antioxidants and other bio products that work with the skin and hair’s own physiology to combat the effects of the normal aging process, according to the company.
ReGenica is the product of newborn fibroblasts that the company keep in an ‘embryonic like state’ using bioreactors that mimic the embryonic environment.
In this way, the fibroblasts can be encouraged to produce the growth factors and antioxidants that make up ReGenica.
Histogen Aesthetic will distribute its products via physicians’ offices, an increasingly popular choice for cosmeceutical products.
“The market for next generation, novel cosmeceuticals is rapidly evolving, including the movement of physician dispensed, non-prescription products beyond the traditional medical specialties of plastic surgery and cosmetic dermatology, and into other medical specialities,” said Dr Lawrence A. Rheins, president of the new venture.
According to Histogen, recent studies illustrated the positive effect the ReGenica complex might have on the skin of patients who have recently undergone cosmetic procedures.
Products to complement treatments
Histogen is not alone in attempting to target this market.
The fruits of Allergan and Clinique’s joint labour hit the shelves of physician’s office only last week.
The products in the Clinique Medical line have been designed to help prepare skin for cosmetic procedures such as microdermabrasion, chemical peels and intense pulsed light therapy, as well as help it to recover post procedure.
